HN2001000218A - Un efecto compuesto derivado de la triptamina y sus analogos - Google Patents

Un efecto compuesto derivado de la triptamina y sus analogos

Info

Publication number
HN2001000218A
HN2001000218A HN2001000218A HN2001000218A HN2001000218A HN 2001000218 A HN2001000218 A HN 2001000218A HN 2001000218 A HN2001000218 A HN 2001000218A HN 2001000218 A HN2001000218 A HN 2001000218A HN 2001000218 A HN2001000218 A HN 2001000218A
Authority
HN
Honduras
Prior art keywords
disorders
conditions
compositions
compounds
triptamine
Prior art date
Application number
HN2001000218A
Other languages
English (en)
Spanish (es)
Inventor
Nava Zisapel
Moshe Laudon
Original Assignee
Neurim Pharma 1991
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Neurim Pharma 1991 filed Critical Neurim Pharma 1991
Publication of HN2001000218A publication Critical patent/HN2001000218A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/04—Indoles; Hydrogenated indoles
    • C07D209/10—Indoles; Hydrogenated indoles with substituted hydrocarbon radicals attached to carbon atoms of the hetero ring
    • C07D209/12—Radicals substituted by oxygen atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/12—Drugs for genital or sexual disorders; Contraceptives for climacteric disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A61P39/06—Free radical scavengers or antioxidants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/06—Drugs for disorders of the endocrine system of the anterior pituitary hormones, e.g. TSH, ACTH, FSH, LH, PRL, GH
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/04—Indoles; Hydrogenated indoles
    • C07D209/10—Indoles; Hydrogenated indoles with substituted hydrocarbon radicals attached to carbon atoms of the hetero ring
    • C07D209/14—Radicals substituted by nitrogen atoms, not forming part of a nitro radical
    • C07D209/16—Tryptamines

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Diabetes (AREA)
  • Endocrinology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Reproductive Health (AREA)
  • Cardiology (AREA)
  • Pain & Pain Management (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Immunology (AREA)
  • Psychiatry (AREA)
  • Obesity (AREA)
  • Psychology (AREA)
  • Biochemistry (AREA)
  • Child & Adolescent Psychology (AREA)
  • Emergency Medicine (AREA)
  • Ophthalmology & Optometry (AREA)
  • Hospice & Palliative Care (AREA)
  • Toxicology (AREA)
  • Anesthesiology (AREA)
  • Gynecology & Obstetrics (AREA)
  • Vascular Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
HN2001000218A 2000-10-03 2001-10-02 Un efecto compuesto derivado de la triptamina y sus analogos HN2001000218A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
IL138825A IL138825A (en) 2000-10-03 2000-10-03 Pharmaceutical preparations containing tryptamine derivatives and similar compounds, and such new compounds

Publications (1)

Publication Number Publication Date
HN2001000218A true HN2001000218A (es) 2002-05-09

Family

ID=11074694

Family Applications (1)

Application Number Title Priority Date Filing Date
HN2001000218A HN2001000218A (es) 2000-10-03 2001-10-02 Un efecto compuesto derivado de la triptamina y sus analogos

Country Status (39)

Country Link
US (2) US6780884B2 (enExample)
EP (1) EP1331935B1 (enExample)
JP (1) JP2004533986A (enExample)
KR (1) KR100855385B1 (enExample)
CN (1) CN100518735C (enExample)
AR (1) AR035587A1 (enExample)
AT (1) ATE409474T1 (enExample)
AU (1) AU9416201A (enExample)
BG (1) BG107759A (enExample)
BR (1) BR0114464A (enExample)
CA (1) CA2423628C (enExample)
CL (1) CL2001002303A1 (enExample)
CR (1) CR6968A (enExample)
CY (1) CY1110417T1 (enExample)
CZ (1) CZ301098B6 (enExample)
DE (1) DE60136003D1 (enExample)
DK (1) DK1331935T3 (enExample)
EA (1) EA005918B1 (enExample)
EE (1) EE05192B1 (enExample)
ES (1) ES2315307T3 (enExample)
GT (1) GT200100197A (enExample)
HN (1) HN2001000218A (enExample)
HU (1) HU227163B1 (enExample)
IL (1) IL138825A (enExample)
IS (1) IS2607B (enExample)
MX (1) MXPA03002612A (enExample)
NO (1) NO20031396L (enExample)
NZ (1) NZ525587A (enExample)
PA (1) PA8529801A1 (enExample)
PE (1) PE20020411A1 (enExample)
PL (1) PL365679A1 (enExample)
PT (1) PT1331935E (enExample)
SI (1) SI1331935T1 (enExample)
SK (1) SK4042003A3 (enExample)
TW (1) TWI270544B (enExample)
UA (1) UA75091C2 (enExample)
UY (1) UY26946A1 (enExample)
WO (1) WO2002028347A2 (enExample)
ZA (1) ZA200303113B (enExample)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1694323A4 (en) * 2003-12-19 2009-05-13 Elixir Pharmaceuticals Inc METHOD FOR TREATING A DISEASE
MXPA06009377A (es) * 2004-02-20 2007-03-07 Lifescape Biosciences Inc Composiciones y metodos para regulacion del sueno.
AU2006257815A1 (en) * 2005-06-10 2006-12-21 Bipar Sciences, Inc. PARP modulators and treatment of cancer
US7622495B2 (en) * 2006-10-03 2009-11-24 Neurim Pharmaceuticals (1991) Ltd. Substituted aryl-indole compounds and their kynurenine/kynuramine-like metabolites as therapeutic agents
KR101760139B1 (ko) 2007-06-29 2017-07-31 클라렌슈 피티와이 리미티드 안투여를 통한 신경 또는 신경정신 장애의 치료 또는 예방용 약학 조성물
HRP20151367T1 (hr) * 2008-05-13 2016-01-29 Yale University Kimerne male molekule za pojaäśanje odgovora protutijela na stanice raka
US8852630B2 (en) 2008-05-13 2014-10-07 Yale University Chimeric small molecules for the recruitment of antibodies to cancer cells
CN103841890B (zh) 2011-05-31 2017-10-27 克拉伦苏股份有限公司 预防和治疗运动相关神经系统疾病的方法
US9073851B2 (en) 2011-10-28 2015-07-07 Board Of Regents, The University Of Texas System Compositions and methods for treating cancer
CN102816103B (zh) * 2012-08-20 2014-05-07 冉瑞琼 硫化天冬氨酸修饰的退黑素衍生物及其应用
TWI733772B (zh) * 2016-03-14 2021-07-21 美商身體邏輯股份有限公司 用於合成吲哚環核鹼基結合物之組成物及方法
CN116421600B (zh) * 2023-05-29 2024-08-23 重庆医科大学 色醇在制备治疗焦虑的药物中的应用
WO2025137730A1 (en) * 2023-12-22 2025-06-26 Alexander Shulgin Research Institute, Inc. N-substituted tryptamines and n-substituted lysergamides and their use as therapeutic agents

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL79264A0 (en) * 1986-06-27 1986-09-30 Univ Ramot Tryptamine derivatives,pharmaceutical compositions containing them and their use in an assay for melatonin receptors
AUPO274596A0 (en) * 1996-10-04 1996-10-31 Armstrong, Stuart Maxwell Method for the treatment of neurological or neuropsychiatric disorders
US6310085B1 (en) * 1997-10-03 2001-10-30 Clarencew Pty Ltd. Method for the treatment of neurological or neuropsychiatric disorders

Also Published As

Publication number Publication date
UY26946A1 (es) 2001-11-30
ZA200303113B (en) 2004-07-23
CN100518735C (zh) 2009-07-29
NO20031396D0 (no) 2003-03-27
GT200100197A (es) 2002-05-08
EA200300436A1 (ru) 2003-10-30
HU227163B1 (en) 2010-09-28
EE200300135A (et) 2003-08-15
JP2004533986A (ja) 2004-11-11
IS6752A (is) 2003-03-21
CZ301098B6 (cs) 2009-11-04
CA2423628C (en) 2011-04-26
PE20020411A1 (es) 2002-05-16
ES2315307T3 (es) 2009-04-01
US6780884B2 (en) 2004-08-24
KR100855385B1 (ko) 2008-09-04
CA2423628A1 (en) 2002-04-11
US20040029950A1 (en) 2004-02-12
EP1331935B1 (en) 2008-10-01
WO2002028347A2 (en) 2002-04-11
IL138825A0 (en) 2001-10-31
IS2607B (is) 2010-04-15
IL138825A (en) 2006-06-11
WO2002028347A3 (en) 2002-07-04
EP1331935A2 (en) 2003-08-06
NZ525587A (en) 2005-03-24
EE05192B1 (et) 2009-08-17
CZ2003940A3 (cs) 2003-10-15
EA005918B1 (ru) 2005-06-30
DK1331935T3 (da) 2009-02-02
AR035587A1 (es) 2004-06-16
MXPA03002612A (es) 2004-04-02
CN1582147A (zh) 2005-02-16
TWI270544B (en) 2007-01-11
CY1110417T1 (el) 2015-04-29
BR0114464A (pt) 2004-01-20
PL365679A1 (en) 2005-01-10
ATE409474T1 (de) 2008-10-15
AU9416201A (en) 2002-04-15
CL2001002303A1 (es) 2010-06-25
SK4042003A3 (en) 2003-09-11
PA8529801A1 (es) 2002-12-30
SI1331935T1 (sl) 2009-04-30
CR6968A (es) 2004-02-25
HUP0302616A2 (hu) 2003-11-28
EP1331935A4 (en) 2004-12-01
KR20030051689A (ko) 2003-06-25
DE60136003D1 (de) 2008-11-13
US20050020664A1 (en) 2005-01-27
BG107759A (bg) 2004-01-30
PT1331935E (pt) 2009-01-19
UA75091C2 (en) 2006-03-15
NO20031396L (no) 2003-03-27
HK1074163A1 (zh) 2005-11-04

Similar Documents

Publication Publication Date Title
AR002289A1 (es) Derivados de acetamida, procedimiento para prepararlos, las composiciones farmaceuticas que los contienen y las aplicaciones de dichos compuestos comoansioliticos y en el tratamiento de enfermedades inmuno-inflamatorias.
AR109590A2 (es) Régimen posológico para inhibidores de comt
ES2119124T3 (es) Bencimidazoles utiles para el tratamiento de trastornos del sistema nervioso.
CL2004000848A1 (es) Compuestos derivados de fenacil-2-hidroxi-3-diaminoalcanos, inhibidores de la enzima betasecretasa, utiles para preparar un medicamento para tratar alzheimer, sindrome de down, hemorragia cerebral hereditaria con amiloidosis de tipo holandes, y otras
CY1110417T1 (el) Παραγωγα τρυπταμινης και αναλογες ενωσεις και φαρμακευτικες φαρμακοτεχνικες μορφες που περιεχουν αυτα
BR0212617A (pt) Compostos de pirazolila substituìdo para o tratamento de inflamação
UY28482A1 (es) Nuevos compuestos
GT199900068A (es) Composiciones solidas que contienen gabapentina y proceso para su preparacion.
AR002705A1 (es) Un nuevo compuesto de indolina, un proceso para su preparacion y composiciones farmaceuticas que lo contienen.
CU23112A3 (es) AMINOáCIDOS BICICLICOS COMO AGENTES FARMACéUTICOS
BR0212611A (pt) Compostos de pirazolila substituìdos para o tratamento da inflamação
ECSP034810A (es) Derivados heterociclilalcoxi-, -alquiltio- y - alquilaminobenzazol tales como ligandos 5-hidroxitriptamina-6
BR112015018168A2 (pt) inibidores de rock suaves
CO2021007402A2 (es) Constructos de suministro para transcitosis y métodos relacionados
CO6410283A2 (es) Métodos para administrar (4ar,10ar)-1-n-propil-1,2,3,4,4a,5,10,10a-octahidro-benzo[g]quinolin-6,7-diol y compuestos relacionados a través de la mucosa oral, la mucosa nasal o la piel, y sus compoisiciones farmacéuticas
CU24713B1 (es) Compuestos aromáticos bicíclicos derivatizados por ácido fenilacético y bencilamina, útiles en el tratamiento de trastornos inmunológicos, enfermedades del sistema nervioso central, neurodegenerativas, renales y cardiovasculares
EA200702646A1 (ru) Композиции для инъекций и способ приготовления данных композиций
CO2024015524A2 (es) Compuestos aromáticos que contienen boro y análogos de insulina relacionados
CL2023000086A1 (es) Análogos de insulina novedosos y usos de estos(div 202201400)
PA8542601A1 (es) Bifenilcarboxamidas reductoras de lipidos
ECSP034804A (es) Aminoácidos bicíclicos o tricíclicos condensados
CO2021006814A2 (es) Proceso para la producción de formas farmacéuticas que contienen inhibidores de los canales task–1 y task–3 y su uso para la terapia de trastornos respiratorios
MX9305510A (es) Compuestos para el tratamiento o profilaxis de desordenes gastrointestinales, cardiovasculares y del sistema nervioso central, procedimiento para su preparacion y composiciones farmaceuticas que los contienen.
ES2160240T3 (es) Benzamidas para el tratamiento de desordenes neurodegenerativos.
DK1645558T3 (da) Piperazinylpyraziner som serotonin 5-HT2C receptormodulatorer